Vardi J, Flechter S, Oberman Z, Rosenbaum M, Regev I
Riv Neurol. 1979 Jul-Aug;49(4):291-6.
The activity of DBH enzyme was measured in plasma of 7 non treated patients suffering from Parkinson's disease; a 10 mg dose of Bromocryptine was administered per os to these patients. Attained results were compared to the enzyme activity in a group of control of 7 healthy individuals. It was pointed out that in patients suffering from Parkinson's disease the decrease of DBH level in plasma after the administration of Bromocryptine was of 32.6% +/- SE 4.4% while in the group of control the decrease was only of 15% +/- SE 4.9%. This decrease in the plasmatic level of the enzyme after the administration of Bromocryptine should be due to the marked antagonistic activity of Bromocryptine on pre-synaptic dopaminergic receptors. This should mean that peripheric pre-synaptic dopaminergic receptors are involved in the physiopathology of Parkinson's disease.
对7名未经治疗的帕金森病患者的血浆进行了DBH酶活性测定；给这些患者口服10毫克剂量的溴隐亭。将所得结果与7名健康个体组成的对照组中的酶活性进行比较。结果指出，帕金森病患者服用溴隐亭后血浆中DBH水平下降了32.6%±标准误4.4%，而对照组中下降仅为15%±标准误4.9%。服用溴隐亭后酶的血浆水平下降应归因于溴隐亭对突触前多巴胺能受体的显著拮抗活性。这意味着外周突触前多巴胺能受体参与了帕金森病的病理生理过程。
